Active ingredientSotorasibCat. No. P-S070-001CAS 2252403-56-6Family · Pharmaceutical analytical standards
Sotorasib
An anticancer drug that blocks the KRAS protein carrying the G12C mutation, approved in the United States in May 2021 and in the European Union in January 2022 for non-small cell lung cancer. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was the first targeted therapy approved for tumours with any KRAS mutation: it locks irreversibly onto the sulphur atom of the cysteine found in the mutated protein.
Go to the active ingredient →Active ingredientSotorasibCat. No. P-S070-001CAS 2252403-56-6
MetaboliteSotorasib Metabolite 1Cat. No. P-S070-003
Isotopically labelledSotorasib-d3Cat. No. P-S070-004
Isotopically labelledSotorasib-d7Cat. No. P-S070-005
NitrosamineN-Nitroso Sotorasib Impurity 1Cat. No. P-S070-006
NitrosamineN-Nitroso Sotorasib Impurity 2Cat. No. P-S070-007
NitrosamineN-Nitroso Sotorasib Impurity 3Cat. No. P-S070-008
ImpuritySotorasib Impurity 1Cat. No. P-S070-009CAS 1604376-50-2
ImpuritySotorasib Impurity 2Cat. No. P-S070-010CAS 2484718-65-0
ImpuritySotorasib Impurity 3 TrifluoroacetateCat. No. P-S070-011No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.